Compare Duke Energy Corp (DUK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs TG Therapeutics Inc — how do they compare? Duke Energy Corp trades at $116.65 (market cap $91.10B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Duke Energy Corp is far larger — about 11.2× TG Therapeutics Inc's market cap, and Duke Energy Corp pays a 3.71% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and TG Therapeutics Inc for 16 Days on average.
| DUK | TGTX | |
|---|---|---|
Market Cap | $91.10B | $8.16B |
Volume | 4,199,050 | 1,735,121 |
Sector | Utilities | Health |
52-Week High | $133.46 | $59.06 |
52-Week Low | $113.23 | $26.94 |
Typical Hold Time | 74 Days | 16 Days |
Enterprise Value | $183.61B | $8.37B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.84, up 1.16% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals with a P/E of 17.6, net income margin of 15.78%, and robust cash flow from operations of $12.33B in 2025. Recent news highlights dividend declarations and data center growth opportunities, while analyst consensus is mixed with a $134.44 price target.
DUK offers a stable investment with reliable dividends and growth from data center demand, but faces risks from rising Treasury yields, high debt levels, and regulatory pressures. The stock's valuation is reasonable, and institutional interest remains positive, though technical indicators suggest near-term resistance at $118.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
